Table 5

Correlations of clinicopathological characteristics (CPC) and EphA10/Gli3 expression with the mean survival of patients with invasive BC

CPCCase numberMean survival (years)χ2 P value
Age (years)
 ≤45688.22 (0.2–13.0)0.1340.714
 >45568.99 (0.8–13.0)
Menopausal status
 Premenopausal717.97 (0.2–13.0)2.2610.133
 Postmenopausal539.33 (0.8–13.0)
ER
 +599.75 (0.7–13.0)1.8470.174
 –657.48 (0.2–13.0)
PR
 +649.02 (0.7–13.0)0.0190.891
 –608.05 (0.2–13.0)
CerB2
 +788.17 (0.7–13.0)0.6880.407
 –469.17 (0.2–13.0)
Histologic grades
 Ⅰ1713.51 (11.2–13.0)61.6420.000
 Ⅱ4911.36 (3.0–13.0)
 Ⅲ584.70 (0.2–13.0)
Tumor size
 ≤3 cm5710.11 (1.0–13.0)8.6040.003
 >3 cm677.19 (0.2–13.0)
TNM stage
 Ⅰ + Ⅱ3518.58 (7–30)57.5690.000
 Ⅲ + Ⅳ3811.05 (3–30)
Lymph node metastasis
 No5610.73 (0.8–13.0)9.2140.002
 Yes686.77 (0.2–13.0)
Invasion
 No3317.52 (4–30)17.3990.000
 Yes679.87 (3–30)
EphA10
 –4812.36 (3.0–13.0)30.8740.000
 +766.12 (0.2–13.0)
Gli3
 –5512.35 (2.0–13.0)37.6170.000
 +695.69 (0.2–13.0)
  • BC, breast cancer; ER, estrogen receptor; PR, progesterone receptor; TNM, tumor, node, metastasis.